A Study of the Effects of PEITC on Oral Cells With Mutant p53
NCT01790204 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 55
Last updated 2015-03-23
Summary
The aim of this clinical trial is to examine the effects of phenethyl isothiocyanate (PEITC), a compound derived from cruciferous vegetables, on oral cells with mutant p53. The p53 protein's normal (wild-type) function within cells is to act as a tumor suppressor, or anti-cancer protein. When mutated, the p53 protein not only no longer executes the functions of a tumor suppressor, and it can gain functions as a pro-cancer protein.22 The proposed clinical trial will utilize oral cells collected from subjects who are heavy smokers. Since the subjects are regularly exposed to mutagenic chemicals it is the thought that their oral cells will contain measurable levels of mutant p53. The participants will consume watercress juice, which is rich in PEITC (See Figure 1). Previous studies in the laboratory showed PEITC selectively depletes mutant p53, and not wild type p53, in cell culture. Our hypothesis is that the ITC in the watercress juice will lead to the depletion of mutant p53 within the oral cells. This depletion could lead to a possible clinical application of this compound, such as chemopreventives or oncologic treatments of individuals with oral cancers.
Conditions
- Oral Cancer
Interventions
- DIETARY_SUPPLEMENT
-
Watercress Juice
The juice is prepared, by a trained member of the Chung laboratory staff, in the following manner; each serving of watercress juice will be prepared with 55gm watercress (from a local grocery store) with 220 ml purified water, for a proportion of 1:4 (w/w). The watercress and water will be placed in a 1.5 L mechanical blender and blended at low speed for approximately 15 seconds, followed by blending at a high speed for one additional minute. The resulting suspension will be filtered through two layers of cheese cloth. Remaining liquids will be manually extracted from the cheese cloth into the same container. Each serving will be measured to 200 ml. The remaining 20 ml will be used for analysis of ITC content. Each serving will be prepared and kept at 40 C until needed, no more than one hour prior to participant consumption by the subject.
Sponsors & Collaborators
-
Georgetown University
lead OTHER
Principal Investigators
-
Fung-Lung Chung, Ph.D. · Lombardi Comprehensive Cancer Center
Study Design
- Allocation
- NA
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 20 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-02-29
- Primary Completion
- 2014-04-30
- Completion
- 2014-04-30
Countries
- United States
Study Locations
More Related Trials
-
A Phase II Trial of PG2 in Patients With Advanced Pharyngeal or Laryngeal Squamous Cell Carcinoma Under Concurrent Chemoradiotherapy
NCT01720563 ·Status: TERMINATED ·Phase: PHASE2
-
Evaluating Treatment Strategies for p53 Mutant Oral Cancer and Oral Cancer Precursors
NCT07090070 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Efficacy of an Oral Immunomodulatory Nutrient on Survival During Postoperative Concomitant Chemoradiotherapy in Head and Neck Cancer
NCT04001543 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Effects of (Licochalcone A) and Paclitaxel on Human Oral Squamous Cell Carcinoma Cell Line
NCT03292822 ·Status: COMPLETED ·Phase: PHASE1
-
Bioavailability and Mucosal Bioactivity of Avmacol® in Healthy Volunteers
NCT02800265 ·Status: COMPLETED ·Phase: NA
-
Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in Firefighters
NCT06009926 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Effects of Avmacol® in the Oral Mucosa of Patients Following Curative Treatment for Tobacco-related Head and Neck Cancer
NCT03268993 ·Status: COMPLETED ·Phase: NA
-
Chemical and Genetic Effects of the Experimental Anti-Cancer Drugs in Cheek Cells in Cancer Patients
NCT00055380 ·Status: COMPLETED ·Phase: PHASE1
-
Freeze-Dried Black Raspberries in Preventing Oral Cancer Recurrence in High At-Risk Appalachian Patients Oral Cancer Survivors
NCT01504932 ·Status: COMPLETED ·Phase: NA
-
Chemoprevention Study of Oral Cavity Squamous Cell Carcinoma
NCT00201279 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical and Immunohisochemical Evaluation of Chemopreventive Effect of Thymoquinone on Oral Potentially Malignant Lesions.
NCT03208790 ·Status: COMPLETED ·Phase: PHASE2
-
A Pharmacokinetic Study of Nutri-PEITC Jelly in Head and Neck Cancer Survivors
NCT03700983 ·Status: COMPLETED ·Phase: NA
-
Exfoliated Cytology in Detection of Oral Premalignant and Malignant Lesions
NCT04955197 ·Status: UNKNOWN
-
Effect of Quercetin in Prevention and Treatment of Oral Mucositis
NCT01732393 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Food Supplements Based on Nettle and Peppermint to Control Signs and Symptoms Induced by Cancer Therapies
NCT04474951 ·Status: UNKNOWN ·Phase: NA
-
In-vitro Effect of Mangosteen Pericarp Extract on Cell Lines
NCT03728192 ·Status: COMPLETED ·Phase: NA
-
Diagnostic Aids for Detection and Diagnosis of Oral Cancer
NCT02251639 ·Status: WITHDRAWN ·Phase: PHASE1
-
Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention
NCT01192204 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer.
NCT01469429 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Broccoli Sprout Extract in Preventing Recurrence in Patients With Tobacco-Related Head and Neck Squamous Cell Cancer
NCT03182959 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer
NCT05966194 ·Status: RECRUITING ·Phase: PHASE2
-
Oral Health and Oral Health-Related Quality of Life in Early Stage Breast Cancer Survivors
NCT01272570 ·Status: COMPLETED
-
Effect of Cannabis and Cigarette Smoking on Oral Mucosa
NCT03334279 ·Status: UNKNOWN
-
Myeloid-derived Suppressor Cells (MDSCs) in OSCC Patients
NCT04387682 ·Status: UNKNOWN ·Phase: NA
-
Randomised Study of Mucositis Prevention After Radiochemotherapy Treatment for Head and Neck Cancer
NCT01149642 ·Status: COMPLETED ·Phase: NA